Skip to main content
kainos loboratories,inc logo

kainos loboratories,inc — Investor Relations & Filings

Ticker · 4556 ISIN · JP3205650009 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-05-25 Share Issue/Capital Cha…
Country JP Japan
Listing T 4556

About kainos loboratories,inc

https://www.kainos.co.jp/en/

Kainos Laboratories, Inc. is a company focused on the development, manufacture, marketing, and distribution of in-vitro diagnostics and pharmaceuticals. As a pioneer in its field, the company specializes in creating innovative clinical testing reagents for biochemical, immunological, and genetic analysis. These diagnostic tools are used to examine biological samples, such as blood and urine, to provide data on a patient's health status. The company is committed to developing and supplying novel products to meet the needs of the medical and healthcare communities.

Recent filings

Filing Released Lang Actions
臨時報告書
Share Issue/Capital Change Classification · 91% confidence The document is a Japanese “臨時報告書” filed under the Financial Instruments and Exchange Act to disclose the results of an Extraordinary General Meeting, including the resolution to consolidate (reverse split) shares (235,000 shares into one), amendments to the articles of incorporation, and related corporate actions (share consolidation leading to delisting). These details constitute a capital change announcement (share consolidation). Therefore, the most appropriate category is Share Issue/Capital Change (SHA).
2026-05-25 Japanese
株式併合、単元株式数の定めの廃止及び定款の一部変更に係る承認決議に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a formal announcement of an approved extraordinary shareholders meeting to implement a stock consolidation (reverse split), abolishment of unit share number, and corresponding amendments to the articles of incorporation. It contains detailed terms of the consolidation ratio, effective dates, and post-consolidation capital structure. This is a classic corporate action altering the share capital and share structure rather than a general regulatory update or earnings release. Therefore the correct classification is Share Issue/Capital Change (SHA).
2026-05-25 Japanese
臨時報告書
Share Issue/Capital Change Classification · 82% confidence The document is a Japanese 臨時報告書 (“Timely Report”) filed under the Financial Instruments and Exchange Act, disclosing the Board resolution to convene an extraordinary shareholders’ meeting for a one-for-235,000 share consolidation (reverse stock split). It is not merely an announcement of an attached report but the full disclosure of a capital change event. This falls squarely under “Share Issue/Capital Change” (Code: SHA).
2026-04-22 Japanese
株式併合、単元株式数の定めの廃止及び定款の一部変更に関するお知らせ
Regulatory Filings
2026-04-22 Japanese
自己株式の消却に関するお知らせ
Regulatory Filings
2026-04-22 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. H1 51
2025-11-06 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.